CRISPR Study Sends Biotech Stocks Tumbling

On Monday, a new paper had identified a possible barrier to using the revolutionary gene-editing tool CRISPR in humans. The news sent the stocks of all three major CRISPR biotech firms tumbling in premarket trading. They declined by as much as 11.9 percent. In recent years, CRISPR has been credited with the potential power to correct any number of devastating diseases.
%d bloggers like this: